Ajanta Pharma Limited · NSE:AJANTPHARM
Ajanta Pharma — Q1 FY2027 Earnings Presentation
41 slides from Ajanta Pharma's earnings presentation, Jul 30, 2026
Slide 1: Investor Presentation Q1 FY 2027
Investor Presentation Q1 FY 2027 30th July 2026
Slide 2: Important Disclosure
Important Disclosure Except for the historical information contained herein, statements in this presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would’, 'believe', 'may', 'expect', 'will continue', 'anticipate', 'estimate', 'in
Slide 3: Table of Contents
TABLE OF CONTENTS 01 02 03 04 Ajanta at a Branded US Africa Glance Generics Generics Institution 05 06 07 R&D & Mfg Financials Strategy 30th July 2026 3
Slide 4: Ajanta at a Glance
Ajanta at a Glance Strong Performance. Accelerating Growth. 30th July 2026 4
Slide 5: We are present in 34+ countries globally
We are present in 34+ countries globally Generics Branded Generics Africa India Rest of Asia USA 21 countries 11 countries 30th July 2026 5
Slide 6: Branded Generic – The Strategic Core
Q1 FY 2027 Branded Generic – The Strategic Core 2/3rd of business comes from branded generics 50% of our products are 1st to Market US 500+ Generics India 30% 32% Brands across Different Therapeutic Segments Africa Instn. 4% Asia Africa 16% 6,050+ 18% Medical Representatives Rs. 1,616 cr. Promoting
Slide 7: Our Branded Generics business comes from 3 regions
Q1 FY 2027 Our Branded Generics business comes from 3 regions Presence in India, Africa & Asia Focus on Chronic Therapies (Cardiac, Diabetics, Ophthal, Derma, Pain, Gynaec) We hold Leadership In Molecules & Sub-Therapeutic Segments 30th July 2026 7
Slide 8: Our Business is well diversified & gives us an edge
Q1 FY 2027 Our Business is well diversified & gives us an edge 6 Branded Generics - Branded Generics - 8 T Segments T Segments India Asia & Africa ~50% Leading First to market Brands in Segments 330+ 220+ Products Products 55 Antimalarial Active ANDAs T Segment (excld. 5 Tentative) 17 1st Under Appr
Slide 9: Branded Generics - India
Q1 FY 2027 Branded Generics -India Excellent Growth Momentum 30th July 2026 9
Slide 10: Ranked in Ophthalmology in India
Ranked 1 1k 10 ml 5ml Sooium Carlxocy- ~ rre~lulose 0.5 %w/v Moxifloxacin &GlycerirA 35%w/v Eye Drops IP 1 Eye Drops. 0.5% w/v apdrops EyeOrops So tdro s• l-Ubriullng Ey,, Drops in Ophthalmology in ln:dia Slenle ajanta s: ajatda ajanta Where Excellence is a way of life 30th July 2026 10
Slide 11: India 3-year CAGR – Consistent Solid Growth
Q1 FY 2027 India 3-year CAGR – Consistent Solid Growth Revenue (Rs. Cr.) 3-Years Ajanta’s Segment CAGR Source: Company Source: IQVIA, MAT March 2024 to 2026 1,654 1,452 18% 1,308 17% 15% 13% 9% FY24 FY25 FY26 Ajanta Cardiac Ophthal Derma Pain 30th July 2026 11
Slide 12: High Focus on Chronic Segment in India
Q1 FY 2027 High Focus on Chronic Segment in India 65% 11% 53% Chronic Portfolio India sales under NLEM Top 10 brands contribute 3,750+ 8 17 MRs New launches in Q1 Brands above Rs. 25+ cr. 30th July 2026 12
Slide 13: We continue to outperform IPM growth
Q1 FY 2027 We continue to outperform IPM growth IPM v/s Ajanta Growth Growth Break-up IQVIA MAT Jun 2026 Ajanta (15.1%) 7th 16% 15% IPM (11.1%) 13% 5.4% 11% 11% ~ 1.8X 10% 9% 3.1% to IPM 8% 8% 8% 4.9% 4.6% Mar-23 Mar-24 Mar-25 Mar-26 Jun-26 4.7% 3.4% ~ 1.4X to IPM IPM Ajanta Pharma Volume Price New
Slide 14: Our most of the segment growth exceeds IPM
Q1 FY 2027 Our most of the segment growth exceeds IPM IPM v/s Ajanta Growth 9th 1st 1st 5th Cardiac Opthal Derma Pain 15% 15% 15% 14% 10% 10% 9% 8% Jun-26 Jun-26 Jun-26 Jun-26 IPM Ajanta Pharma Covered Market Rank IPM = Indian Pharmaceutical Market, Source: IQVIA, MAT June 2026 30th July 2026 14
Slide 15: India – Sales at glance
Q1 FY 2027 India – Sales at glance Sales Contribution Revenue Q1 FY 2027 Source: IQVIA MAT June 2026 Source: P&L (Rs. cr.) Nephro,Gyanec, 1% 1% Pain 24% 10% Cardiac 509 Focus on 37% 409 Derma 22% 6 specialty therapies Ophthal 29% Q1 FY26 Q1 FY27 30th July 2026 15
Slide 16: Branded Generics – Asia & Africa
Q1 FY 2027 Branded Generics – Asia & Africa Diversified markets enables growth 30th July 2026 16
Slide 17: We operate across many markets and therapies in EM
Q1 FY 2027 We operate across many markets and therapies in EM Key Markets Leadership Among Africa, Southeast Asia, Middle In many molecules & Top 5 sub-therapeutic segments Players in major markets East & Central Asia EM = Emerging Markets 30th July 2026 17
Slide 18: EM: We launched many new products
Q1 FY 2027 EM: We launched many new products Major Therapeutic segments Cardiology Diabetes Ophthalmology Dermatology Pain Gynaecology Antibiotics Antimalarial 6 Pipeline of healthy New Focus New launches Strengthening countries product registrations of small presence & new entry Q1 FY 2027 EM = Eme
Slide 19: 3 Years of Growth in Asia & Africa
Q1 FY 2027 3 Years of Growth in Asia & Africa Revenue (Rs. Cr.) Asia Africa 861 1,191 1,176 750 1,057 585 FY24 FY25 FY26 FY24 FY25 FY26 Source: Company data 30th July 2026 19
Slide 20: EM – Mixed performance
Q1 FY 2027 EM – Mixed performance Asia Rs. Cr. Africa Rs. Cr. 16% 30% 304 Africa 295 255 Excellent growth 228 Asia War impacted Q1 FY26 Q1 FY27 continues Q1 FY26 Q1 FY27 EM = Emerging Markets 30th July 2026 20
Slide 21: US Generics
Q1 FY 2027 US Generics Yet another super performance 30th July 2026 21
Slide 22: US: Holding strong
Q1 FY 2027 US: Holding strong Revenue (Rs. Cr.) 55 51 1,557 Active ANDA Products on shelf (3 approval in Q1 FY 2027) (2 launched in Q1 FY 2027) 1,047 964 17 8-12 Pending approvals Filing Target FY24 FY25 FY26 Source: Company data 30th July 2026 22
Slide 23: US Sales – Outstanding performance
Q1 FY 2027 US Sales – Outstanding performance Revenue (Rs. Cr.) 57% 487 310 Q1 FY26 Q1 FY27 Source: P&L 30th July 2026 23
Slide 24: Antimalarial Institution
Q1 FY 2027 Antimalarial Institution In line performance 30th July 2026 24
Slide 25: Antimalarial Institution business in Africa
Q1 FY 2027 Antimalarial Institution business in Africa Revenue 3 years Revenue Q1 FY 2027 (Rs. Cr) (Rs. Cr.) 83% 249 70 160 147 38 FY24 FY25 FY26 Q1 FY26 Q1 FY27 30th July 2026 25
Slide 26: R&D and Manufacturing
Q1 FY 2027 R&D and Manufacturing Strong formulation capabilities 30th July 2026 26
Slide 27: R&D operating efficiently
Q1 FY 2027 R&D operating efficiently 850+ Scientists R&D Expenses (Excluding Capex) (Rs. Cr. / % to revenue) 5% 5% 5% 4% 252 208 224 66 FY 2024 FY 2025 FY 2026 Q1 FY 27 30th July 2026 27
Slide 28: Our 7 plants are best in class
Q1 FY 2027 Our 7 plants are best in class - major ones being Paithan Dahej (Maharashtra) (Gujarat) Guwahati Pithampur (Assam) (Madhya Pradesh) 30th July 2026 28
Slide 29: Financial Highlights (Consolidated)
Q1 FY 2027 Financial Highlights (Consolidated) Performance at best 30th July 2026 29
Slide 30: Branded Generics – India & Africa grew exceptionally
Q1 FY 2027 Branded Generics –India & Africa grew exceptionally 13% 24% 16% 30% Total India Asia Africa (Rs. cr.) (Rs. cr.) (Rs. cr.) (Rs. cr.) 1,059 304 941 509 255 295 409 228 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 32% 16% 18% of Total Revenue of Total Revenue of Total Reve
Slide 31: Overall excellent performance in Q1
Q1 FY 2027 Overall excellent performance in Q1 25% 13% 57% 83% USA Generics Consolidated Branded Generics Africa Institution (Rs. cr.) (Rs. cr.) (Rs. cr.) Sales (Rs. cr.) 1,059 487 70 1,616 941 310 1,289 38 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 66% 30% 4% of Total Revenue of Total Revenue
Slide 32: Q1 FY 2027: Great beginning
Q1 FY 2027 Q1 FY 2027 : Great beginning Rs. cr. Q1 FY 2026 % to RO Q4 FY 2026 Q1 FY 2027 % to RO % Growth Revenue from Operations (RO) 1,303 1,422 1,626 25% COGS (276) 21% (305) (328) 20% Gross Profit 1,027 79% 1,117 1,298 80% 26% Employee Benefit (303) 23% (341) (381) 23% 26% Other Expenses (373) 2
Slide 33: Smart growth continues
Q1 FY 2027 Smart growth continues (Rs. Cr.) (Rs. Cr.) (Rs. Cr.) Revenue Adj. EBITDA and Margin % PAT and Margin % 5,453 28% 27% 27% 28% 19% 20% 19% 21% 4,648 4,209 1,498 1,056 1,268 1,172 920 816 1,626 454 334 FY24 FY25 FY26 Q1 FY27 FY24 FY25 FY26 Q1 FY27 FY24 FY25 FY26 Q1 FY27 14% 13% 14% 3 Year CA
Slide 34: Our performance among best in industry
Q1 FY 2027 Our performance among best in industry ROCE % ROE % CFO & Cash Conversion 33% 67% 92% 38% 33% 25% 25% 1,157 785 32% 529 23% FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 (INR Cr.) 30th July 2026 34
Slide 35: So also Earnings & Pay Out
Q1 FY 2027 So also Earnings & Pay Out (Rs.) (Rs. Cr.) (Rs.) EPS Payout & PAT % Book Value per share 362 85 79% 76% 33% 74 303 283 65 701 642 350 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 Payout includes Dividend and Buyback 30th July 2026 35
Slide 36: We continue to improve on working capital front
Q1 FY 2027 We continue to improve on working capital front (Nos.) (Nos.) (Nos.) Receivable Days Inventory Days Payable Days 73 125 72 100 109 85 94 75 63 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 30th July 2026 36
Slide 37: Strategy
Strategy Levers for growth 30th July 2026 37
Slide 38: We continue to work on our strategic priorities
We continue to work on our strategic priorities New products launches across markets Strong product portfolio under development / registration Gain market share in existing products Focus on field force productivity enhancement Thrust on new countries & therapies Adding therapies, products & field i
Slide 39: Earnings Call
Earnings Call Let’s Talk 30th July 2026 39
Slide 40: Q1 FY27 Earnings Conference Call
Q1 FY27 Earnings Conference Call Date and Time July 30, 2026 at 16:15 – 17:15 hrs IST 18:45 – 19:45 hrs SST/HKT 11:45 – 12:45 hrs BST 06:45 – 07:45 hrs US ET Dial-in Numbers Diamond pass link Click here to register for faster access Universal Access Primary Access: +91 22 6280 1542 +91 22 7115 8372
Slide 41: Thank you
For more information, please visit our website: www.ajantapharma.com For regular updates follow us on twitter https://x.com/ajantapharmaltd For specific queries, contact: Thank you Rajeev Agarwal: 022-60609706 [email protected] Abhineet Kumar: 022-60609721 [email protected]